INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
03/11/2026
Back to search
Official data from USPTO
PLATON
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
03/12/2026
Trademark type
Word
Nice classes
5, 42
Filing date
03/09/2018
Registration date
12/25/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/11/2025
Last transaction
03/12/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
33
Owner location
FR
Examiner
EVANKO, PATRICIA MALESARDI
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Valerio Therapeutics S.A.
ONXEO
Representatives
Mark Lebow Ladas & Parry
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Products for medical usepharmaceutical products for use in oncologyespecially oligonucleotidesmore particularly in the form of double-stranded DNA acting as a decoy or false signal for proteinsespecially enzymesinvolved in tumor growth and/or tumor escapemore particularly DNA binding proteins and especially tumor cell DNA repair proteins for treating solid and/or liquid cancers
Class 42
Scientificmedical and pharmaceutical research for the research and identification of new pharmaceutical products limited to these oligonucleotides from a proprietary technology platform or chemo-library; pharmaceutical research and development limited to products based on oligonucleotides from a proprietary technology platform or chemo-library; laboratory research limited to pharmaceutical products based on oligonucleotides from a proprietary technology platform or chemo-library; laboratory analysis limited to pharmaceutical products based on oligonucleotides from a proprietary technology platform or chemo-library
Publications
History of USPTO decisions and trademark events.
29 publications found
C71T
CANCELLED SECTION 71
07/11/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/25/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/18/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
08/18/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/26/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/04/2019
FIMP
FINAL DISPOSITION PROCESSED
04/04/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/25/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
12/25/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/09/2018
PUBO
PUBLISHED FOR OPPOSITION
10/09/2018
GPNX
NOTIFICATION PROCESSED BY IB
10/07/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/19/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/19/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/19/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/08/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/07/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/07/2018
RFNT
REFUSAL PROCESSED BY IB
08/04/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/16/2018
RFRR
REFUSAL PROCESSED BY MPU
07/16/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/06/2018
MAFR
APPLICATION FILING RECEIPT MAILED
07/06/2018
CNRT
NON-FINAL ACTION WRITTEN
07/05/2018
DOCK
ASSIGNED TO EXAMINER
07/02/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/02/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/28/2018
Continuous trademark protection
Get notified about every new filing that threatens PLATON or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.